OnCo

Stay in the loop

Leave your email and OnCo will write when something big changes in cancer research. No spam, one click to unsubscribe.

Email updates open shortly. Until then, press Watch on any page to keep it on your list.

drugsTreatmentPhase 2

Evexomostat

aka SDX-7320

Evexomostat is a small-molecule inhibitor from SynDevRx, Inc., in registered phase 2 trials for metastatic cancer.